profit from every $100 of sales.
$0$100
Incyte
$120.97-0.60% today
+14.8% in 1 year
1-year low $90.301-year high $129.93
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $19.16 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Incyte sold, what it kept, and what it did with the cash.
Sales went from $3.39 billion in 2022 to $5.14 billion in 2025, with $1.29 billion of profit last year.
SalesProfit
Incyte vs. similar companies
Incyte grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Incyte | 19.2× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
Compare Incyte with IQVIA Holdings
AI analysis
An AI analyst reads Incyte's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,667 | 2,986 | 3,395 | 3,696 | 4,241 | 5,141 | |
| 2,535 | 2,835 | 3,188 | 3,441 | 3,929 | 4,769 | |
| – | – | 592 | 655 | 101 | 1,343 | |
| -178 | 630 | 600 | 919 | 408 | 1,760 | |
| -296 | 949 | 341 | 598 | 33 | 1,287 | |
| -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | |
| 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% | |
| – | – | 17.4% | 17.7% | 2.4% | 26.1% | |
| -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 3,561 | 4,933 | 5,841 | 6,782 | 5,444 | 6,958 |
| Cash | 1,513 | 2,057 | 2,951 | 3,213 | 1,688 | 3,098 |
| Total debt | – | – | 41 | 38 | 44 | 40 |
| Total liabilities | 950 | 1,163 | 1,471 | 1,592 | 1,997 | 1,790 |
| 2,611 | 3,770 | 4,370 | 5,190 | 3,448 | 5,167 | |
| 218 | 222 | 224 | 226 | 211 | 201 | |
| -7.0% | 12.0% | 9.5% | 12.6% | 7.2% | 25.3% | |
| -11.3% | 25.2% | 7.8% | 11.5% | 0.9% | 24.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -125 | 749 | 970 | 496 | 335 | 1,413 | |
| 187 | 181 | 78 | 47 | 100 | 84 | |
| -312 | 568 | 892 | 449 | 235 | 1,330 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 0 | 2,005 | 0 | |
| 178 | 183 | 188 | 216 | 266 | 249 |
Valuation
- 19.2×
- 16.2×
- –
- 3.6×
- 4.8×
- 18.5×
- 12.3×
- 5.4%
- 5.2%
- 0.0%
Profitability
- 92.8%
- 26.1%
- 25.0%
- 34.9%
- 20.0%
- 13.9%
- 29.3%
- 19.5%
- 24.6%
- 39.1%
Growth
- +14.0%
- –
- +443.9%
- –
- −3.0%
Financial health
- -1.8×
- 0.01
- 0.5%
- 615.9×
- 3.68
- 3.60
- 0.73
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 964
Top 15%of 898
Top 31%of 651
Top 39%of 911
Top 21%of 991
What analysts expect
- Average price target
- $109.50
- Range
- $90.00 – $135.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | 1.81 | 1.38 | +31.2% |
| Feb 10, 2026 | 1.80 | 1.90 | −5.3% |
| Oct 28, 2025 | 2.26 | 1.66 | +36.1% |
| Jul 29, 2025 | 1.57 | 1.39 | +12.9% |
| Apr 29, 2025 | 1.16 | 1.01 | +14.9% |
| Feb 10, 2025 | 1.43 | 1.57 | −8.9% |
| Oct 29, 2024 | 1.07 | 1.12 | −4.5% |
| Jul 30, 2024 | -1.82 | 0.78 | −333.3% |
News
Genmab, Incyte team up to develop experimental colorectal cancer treatmentSeeking Alpha · Oct 25, 2026Specialised Therapeutics to commercialize Incyte’s Opzelura in AustraliaSeeking Alpha · Sep 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
81Pass
Benjamin Graham
69Pass
Philip Fisher
83Pass
Peter Lynch
87Pass
Joel Greenblatt
54No pass
Charlie Munger
86Pass
Terry Smith
80Pass
Questions about Incyte
Is Incyte a good stock to buy?
A strong, very profitable business at a fair price. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Incyte AI analysis
What does Incyte do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. It is in Biotechnology, based in Wilmington, DE, United States, with 2,844 employees.
Does Incyte pay a dividend?
No. Incyte does not pay a dividend at the moment.
Is Incyte stock halal?
Yes. Incyte passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Incyte stock done over the past year?
Up 14.8% over the past twelve months, to $120.97. It traded between $90.30 and $129.93 and is 6.9% below its high.
Who are Incyte's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Incyte's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.